One of the difficulties in the use of reprogrammed cells (iPS cells) is the low efficiency. Now, a technical step has been taken to substantially increase this. Using it, Australian researchers, combining it with the genome editing technique CRISPR-Cas9, have been able to generate normal cells from the cells of two patients, one with retinal cell degeneration and the other a child with severe immune deficiency, which opens the door to its possible clinical use.
Improved efficacy in the generation of iPS cells for clinical use
About the Author: Bioethics Observatory - Institute of Life Sciences UCV
Our website includes “Special Reports” and news, based on the latest biomedical and biotechnological research findings from the world’s top medical and scientific journals. A multidisciplinary editor staff gives a medical and personalistic bioethical assessment. It is also a dynamic means of communication with our readers to reflect on these issues.